ClinicalTrials.gg
Not yet recruitingNCT06330077MODIF-MSUpdated Mar 26, 2024

Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

A Phase 2 interventional study of Ifenprodil and Placebo in Multiple Sclerosis and Remitting Relapsing Multiple Sclerosis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-26.

Primary conditionMultiple Sclerosis, Relapsing-RemittingRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Relapsing-Remitting
Why
  1. The study's listed conditions name Multiple Sclerosis, Relapsing-Remitting, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.

Planned enrollment
52nd of 70
60 · median 154
Started
2024
with 1 other
Phase 2
12 of 82
2 open now
Primary completion
2027-03
later than 5 of 13 live
Registered
75th of 82
by date
Lead sponsor
3 of 82
Assistance Publique - Hôpitaux de Paris

Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 52nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 2 that started in 2024, is one of 12 in phase 2, reaches primary completion later than 5 of the 13 other live ones, and was the 75th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is the most frequently acquired demyelinating disease and the first cause of non-traumatic chronic disability in young adults. Major progress has been achieved in the treatment of MS through the development of therapies targeting the adaptative immune system, which drastically reduce the relapse rate, with various efficiency and safety profiles (Ontaneda, 2015). However, these drugs generally fail to prevent disability worsening along the disease course, and we are now assisting to a shift in therapeutic objectives from the development of new immune drugs towards the identification of therapeutic strategies that could prevent neurodegeneration by promoting myelin regeneration (Stangel, 2017; Stankoff, 2016), in order to prevent neurological disability in MS (Irvine and Blakemore, 2008; Patrikios, 2006; Duncan I, 2017, Bodini, 2016).

Among the first candidate compounds developed to promote remyelination was the anti Lingo1 antibody, which enhance remyelination (Mi, 2009). Medium and large throughput screening of drug libraries subsequently identified several chemical classes of compounds with strong promyelinating properties, such as the antifongic drug miconazole (Najm, 2015) or the muscarinic antagonist clemastine (Wei, 2014). A recent innovative trial has investigated the effect of clemastine, compared to placebo, in a small sample of subjects (25 patients per group) and showed that clemastine could significantly improve the optic nerve conduction speed which reflecting myelin integrity and functionality (Green, 2017).

Our preclinical research has allowed us to identify ifenprodil as a powerful drug to promote myelin repair in vitro and in vivo across species. In parallel our team recently pioneered and optimized a PET imaging approach for quantifying remyelination in the whole brain, that allowed to enhance the sensitivity to detect the myelin repair process, and showed that patients are characterized by heterogeneous profiles of spontaneous remyelination profiles that are closely linked to disability accrual (Bodini, 2016).

03

Conditions studied

  • Multiple Sclerosis
  • Remitting Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Ifenprofil
  • Combination of magnetic resonance imaging (MRI) and positron emission tomography (PET)
  • 18f-Florbetaben
  • Remyelination
04

In context

Multiple Sclerosis, Relapsing-Remitting Reclassified

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's planned enrollment of 60 is close to the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Multiple Sclerosis, Relapsing-Remitting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Patients:

  1. Signed form at pre-inclusion visit
  2. Age between 18 years and 55 years, inclusive, at time of pre-inclusion visit.
  3. Patient with a RR form of MS according McDonald criteria 2017 at pre-inclusion visit
  4. Able to comply with the study protocol and to understand the purpose and risks of the study, in the investigator's judgment
  5. Social security registration (AME excluded) at time of pre-inclusion visit
  6. At least one eye with a P100 latency > 118ms on visual evoked potential at baseline (defining the qualifying eye) at time of pre-inclusion visit
  7. Retinal nerve fibre layer thickness on spectral-domain optical coherence tomography [OCT] > 70 μm in the VEP qualifying eye (to increase the likelihood that the number of surviving axons is sufficient to provide the substrate for remyelination to occur) at time of pre-inclusion visit
  8. Patient under disease modifying therapy (first or approved immune active therapy) or patient without any DMT at time of pre-inclusion visit
  9. EDSS score ≤ 6 at time of pre-inclusion visit
  10. For women of : Efficient include oral contraception, intrauterine devices hormonal device, intrauterine hormone-releasing system, sterilization method and other forms of contraception with failure rate \<1%)

    • Healthy Volunteers
  1. Signed informed consent form 2. Age between 18 years and 55 years, inclusive 3. All female subjects of childbearing potential must practice effective contraception include oral contraception, intrauterine devices hormonal device, intrauterine hormone-releasing system, sterilization method and other forms of contraception with failure rate \<1%) 4. Able to comply with the study protocol, in the investigator's judgment 5. Social security registration (AME excluded)

Exclusion criteria

Exclusion Criteria:

Patients

  1. Patient with an acute NORB in the last 6 months prior to pre-inclusion visit
  2. Patient with a clinical relapse other than NORB in the last 6 months prior to pre-inclusion visit
  3. Patients having received methylprednisolone infusion in the last 4 weeks prior to pre-inclusion visit
  4. to medicinal products (ifenprodil/placebo) and to auxiliary medicinal products (gadolinium, [18F]-florbetaben)
  5. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight ≥ 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, contraindication to gadoteric acid etc.).
  6. PET imaging performed in the past 12 months as part of clinical research
  7. History or incidental discovery of significant cardiac conduction block
  8. Orthostatic hypotension Syndrome define as a drop of > 20 mmHg in systolic, and/or > 10 mmHg in diastolic between lying down and immediate standing
  9. Known long syndrome or long QT syndrome (the limit is defined at 450 ms on corrected QT) highlighted during the pre-inclusion visit
  10. Any uncontrolled general (cancer, infectious, hematologic, hepatic, immunologic, endocrinologic, neurologic, dermatologic, psychiatric, allergic, renal, or cardiovascular) disease.
  11. \< 60 ml/min at pre-inclusion visit
  12. ASAT, ALAT of alkaline phosphatase > 3-fold the upper limit normal at pre-inclusion visit
  13. Know Galactosemia, glucose malabsorption or lactase deficiency
  14. Known of lack of peripheral venous access or lack of peripheral venous access highlighted during the pre-inclusion visit
  15. Thrombocytopenia with \< 100 000/mm3
  16. Pregnancy and/or lactating women
  17. Legal protection (curatorship or tutorship)
  18. Deprive of freedom or under security measure
  19. Participation in another interventional trial evaluating a health product or any randomized trial or being in the exclusion period at the end of a previous study
  20. Refusal to be informed in case of incidental discovery after MRI
  21. Patient treated for hypertension with the following drugs blocking the alpha-adrenergic system either in periphery (prazosine, urapidil, moxisylyte, labetalol) or centrally (clonidine, monoxidine, methyldopa)

Healthy Volunteers

  1. Inability to complete an MRI (contraindications for MRI include but are not restricted to weight ≥ 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc).
  2. Impossibility to complete a PET scan: pregnancy, nuclear medicine irradiation for clinical research in the year preceding baseline visit.
  3. Contraindication to auxiliary medicinal products ([18F]-florbetaben)
  4. Known presence of any neurological disorders
  5. Pregnancy and/or lactation
  6. Lack of peripheral venous access
  7. Terminal renal insufficiency (Creatinin clearance \< 60 ml/min)
  8. Legal protection (curatorship or tutorship)
  9. Deprive of freedom or under security measure
  10. Participation in another interventional trial evaluating a health product or any randomized trial or being in the exclusion period at the end of a previous study
  11. Refusal to be informed in case of clinically significant incidental discovery after MRI
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Ifenprodil

    Ifenprodil : 20mg three time a day (60mg/day). Patients will have an escalation of dose over 48 hours (from Day 1) in order to achieve at the end of the 144 hours (6 days, Day 6) a dose of 60mg/day.

    Drug: Ifenprodil

  • Placebo comparator
    Placebo

    Placebo of ifenprodil : 20mg three time a day (60mg/day). Patients will have an escalation of dose over 48 hours (from Day 1) in order to achieve at the end of the 144 hours (6 days, Day 6) a dose of 60mg/day.

    Drug: Placebo

Interventions

  • Treatment administration

  • DrugPlacebo

    Treatment administration

07

What researchers measure

Primary outcomes

  1. Change in P100 latency according to visual evoked potential.

    Assess the efficacy of ifenprodil on the remyelination of the optic nerve measured as the improvement of P100 latency, assessed using full field visual evoked potentials.

    Time frame: Between months 6 and months 12

Secondary outcomes

  1. Proportion of voxels within white matter lesions classified as remyelinating

    Change in remyelination potential measured by PET-MR Between M6 (end of run-in, calculation of pre-treatment remyelination potential, randomization) and M12 (end of follow-up, calculation of post-treatment remyelination potential) in each group.

    Time frame: Between 6 months and 12 months

  2. Proportion of remyelinating voxels extracted in cortical regions from magnetization transfer imaging (MTR) acquisitions

    Change in the proportion of remyelinating voxels extracted in cortical regions from MTR acquisitions (as cortical myelin in not assessed by PET) between M6 and M12 in each group

    Time frame: Between 6 months and 12 months

  3. Change in amplitude of P100 on to visual evoked potential

    o determine whether the treatment by ifenprodil could influence axonal damage in the visual pathway assessed by the amplitude of P100

    Time frame: Between 6 months and 12 months

  4. Change in retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thickness on OCT

    To determine whether the treatment by ifenprodil could influence neurodegeneration measured by optical coherence tomography (OCT) parameters in each group

    Time frame: Between 6 months and 12 months

  5. Change in blood concentration of NfL fragments

    To determine whether the treatment by ifenprodil could influence axonal damage assessed by the blood concentration of neurofilament light chain (NfL) in each group

    Time frame: From Pre-inclusion visit to 6 months and from 6 months to 9 months and 6 months to 12 months

  6. Change in the brain atrophy rate

    To determine whether the treatment by ifenprodil could influence white matter lesions load or brain atrophy rate in each group

    Time frame: From baseline to 6 months and 6 months to 12 months

  7. The correlation between the change in the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions

    To determine whether the efficacy of ifenprodil is influenced by endogenous remyelination profiles assessed in the run-in period, and to describe the profile of optimal responders

    Time frame: Between 6 months and 12 months and the pre-treatment individual remyelination profiles as determined during the Run-in period

  8. The comparison of the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions

    To assess whether the disease modifying therapies received during the study influence the remyelination level and/or the ifenprodil effect on remyelination

    Time frame: Between 6 months and 12 months

  9. Incidence of adverse drug reactions

    Time frame: Between inclusion and 12 months

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Mar 2027, 36 months later.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 26, 2024
StartEst.
Mar 2024
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Mar 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06330077
Responsible party
Sponsor
First posted
Mar 26, 2024
Start date
Mar 2024 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Mar 26, 2024

Study contacts

Bruno STANKOFF, MD
Contact
bruno.stankoff@aphp.fr
0171970659

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifenprodil

Start the discussion